已发表论文

PD-1 抑制剂纳武单抗(nivolumab)与放疗相结合成功治疗难治性原发性纵隔大 B 细胞淋巴瘤患者:一份病例报告和文献回顾

 

Authors Yan Z, Yao ZH, Yao SN, Xia QX, Wang HY, Chu JF, Song M, Zhao S, Liu YY

Received 15 March 2020

Accepted for publication 8 July 2020

Published 27 July 2020 Volume 2020:12 Pages 6311—6316

DOI https://doi.org/10.2147/CMAR.S254007

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Xueqiong Zhu

Abstract: Primary mediastinal large B-cell lymphoma (PMBCL) is relatively infrequent and generally has a good prognosis with standard immunochemotherapy. However, treatment options are limited for patients with relapsed/refractory PMBCL who are ineligible for stem cell transplantation. In this report, we treated a refractory PMBCL patient, who did not respond to salvage chemotherapy, with combined nivolumab and radiotherapy. The patient achieved a complete remission with mild adverse reactions and has survived without relapse 2 years after treatment.
Keywords: primary mediastinal large B-cell lymphoma, immunotherapy, radiotherapy, nivolumab




Figure 1 Representative images of the rrPMBCL patient during treatment course...